GlaxoSmithKline plc ADR GSK

GlaxoSmithKline plc is a pharmaceutical specialist that researches, develops, and manufactures pharmaceutics, vaccines, and non-prescription medicines. Operating internationally, the company has its headquarters in Brentford, London, and was originally founded in 1715 as an apothecary shop. Employing around 100,000 people, GlaxoSmithKline has production and research and development facilities in more than 30 countries, including the US, the UK, Belgium, China, and Spain.

The company’s operations are divided into four segments – Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. These segments develop and produce therapeutics such as respiratory, HIV, metabolic, and cardiovascular medicines. GlaxoSmithKline also provides general healthcare essentials such as nutritional supplements, nasal sprays, gels, and toothpaste. The company has 43 medicines and 21 vaccines in development as of April 2021.

GlaxoSmithKline trades on the London Stock Exchange using the ticker GSK. In December 2020, it entered into a collaboration and licensing agreement with Icagen, a subsidiary of Ligand Pharmaceuticals Incorporated. The purpose of the agreement is to further research into small molecule therapeutics for the treatment of neurological disorders. As of January 2021, GlaxoSmithKline proceeded with clinical studies on a second coronavirus treatment initiative in partnership with Vir Biotechnology Incorporated.

Add GlaxoSmithKline stock to your eToro watchlist to receive news and updates on GSK share price developments.